The Catalyst
Ultragenyx fell roughly 47% this week after its Phase 3 Aspire trial of apazunersen failed in Angelman syndrome — together, real setbacks in two genuinely different disease areas landing in the same week. On the positive side, Summit Therapeutics rose after partner Akeso reported that ivonescimab beat Keytruda on overall survival in a head-to-head Phase III lung cancer trial, and Tarsus Pharmaceuticals gained on real data from its pending acquisition target, Alkeus. Biotech was roughly flat to modestly positive across market cap tiers this week; medtech lagged, with the micro-cap tier down over 2%.
Sector Performance by Market Cap
Biotech was roughly flat to modestly positive across market cap tiers this week, slightly trailing both XBI (+0.9%) and IBB (+1.4%). Medtech underperformed its own benchmark (XHE −0.8%), with the micro-cap tier down over 2%.
Grouped by lead asset disease category.
Top Gainers & Laggards
Gainers
Partner Akeso reported that ivonescimab demonstrated a statistically significant overall survival benefit versus Keytruda (pembrolizumab) monotherapy in the Phase III HARMONi-2 lung cancer trial — the fourth Phase III readout for the drug to hit its OS endpoint (Summit Therapeutics, 9/2).
Real Phase 3 data published in JAMA Ophthalmology for gildeuretinol — the lead asset of pending acquisition target Alkeus — showed the drug cut retinal lesion growth by 21.6% versus untreated patients in a 50-patient Stargardt disease trial.
Laggards
Phase 3 Aspire trial of apazunersen (GTX-102) failed to meet its primary cognitive endpoint and key secondary endpoint in Angelman syndrome. Multiple analysts downgraded the stock; management is reviewing whether to continue the program.
Two other names showed larger raw % moves this week (ORGS, ONCO/GRI-class microcaps) but were excluded — extremely thin volume and real market caps under $10M make those moves unreliable signal, not real market-moving news.
This Week's Financing Activity
| Company | Stage | Amount | Type |
|---|---|---|---|
| Moderna (MRNA) | Public | $2.0B | Private Placement |
| Jazz Pharmaceuticals (JAZZ) | Public | $1.0B | Notes Offering (Debt) |
| Scan.com | Private | $220M | Financing |
| AusperBio | Private | $120M | Financing |
| Elucid | Private | $55M | Series D |
| N-Power Medicine | Private | $32M | Series B |
| Kardium | Private | $31M | Government Investment |
| Intelligent Bio Solutions (INBS) | Public | $15M | Financing |
The Week's Narrative
A Real Contender to Keytruda Clears Another Bar
Summit Therapeutics' partner Akeso reported that ivonescimab achieved a statistically significant overall survival benefit versus Merck's Keytruda in a head-to-head Phase III trial in first-line PD-L1-positive lung cancer — the fourth Phase III trial for the drug to hit its OS endpoint. The market's reaction was measured rather than euphoric: this result was largely anticipated after the same trial's progression-free survival win in 2024.